Project ACUTETOX
Contact: Dr. Cecilia Clemedson, www.acutetox.eu
Test models included |
Cytotoxicity |
The Caco-2 model |
Colony forming unit-granulocyte/macrophage (CFU-GM) assays |
||
Methods with commercial potential |
Already usedcommercially |
Already used commercially |
Yes |
||
Endpoints |
Acute toxicity |
Subacute and subchronic |
Toxicokinetics and metabolism |
||
Expected field of application |
|
|
|
||
Stage of development |
Basic research onmechanistic end points |
Optimization method |
Pre-validating |
||
Expected regulatory acceptance |
Yes |
|
|
||
Expected interest from the market |
All end users and manufacturers |
|
|
||
| Test models included |
The whole blood assay |
LLC-PK1/TER model for nephrotoxicity |
Different assays for testing neurotoxicity |
Cytomic |
Neural network |
| Methods with commercial potential |
Yes |
Yes |
Yes |
|
|
| Endpoints |
Ecotoxicology |
Blood brain barrier |
Nephrotoxicity |
Hepatoxicity |
|
| Expected field of application |
|
|
|
|
|
| Stage of development |
|
|
|
|
|
Expected regulatory acceptance |
|||||
Expected interest from the market |
|
|
|||

